We compared the percentage of Ki67 positive cells across cancers stratified by the ENDORSE score and found significant difference across the classes at both the baseline (ANOVA P = 4.9 × 10−9; medium risk vs. low risk P = 8.58 × 10−5, high risk vs. low risk P = 0) and at the end of treatment (ANOVA P = 3 × 10−18; medium risk vs. low risk P = 1.6 × 10−6, high risk vs. low risk P = 0) (Fig 6A). This evidence concerns the gene MKI67 and cancer.